[1]冯燕兵,朱洁云,翁文庆.生物可降解激素缓释剂Ozurdex治疗黄斑水肿的研究进展[J].眼科新进展,2016,36(9):889-893.[doi:10.13389/j.cnki.rao.2016.0239]
　FENG Yan-Bing,ZHU Jie-Yun,WENG Wen-Qing.Research progress on biodegradable hormone sustained-release agent Ozurdex for macular edema[J].Recent Advances in Ophthalmology,2016,36(9):889-893.[doi:10.13389/j.cnki.rao.2016.0239]
点击复制

生物可降解激素缓释剂Ozurdex治疗黄斑水肿的研究进展
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
36卷
期数:
2016年9期
页码:
889-893
栏目:
文献综述
出版日期:
2016-09-05

文章信息/Info

Title:
Research progress on biodegradable hormone sustained-release agent Ozurdex for macular edema
作者:
冯燕兵; 朱洁云; 翁文庆
310053　浙江省杭州市，浙江中医药大学（冯燕兵，朱洁云）；314001　浙江省嘉兴市，嘉兴市中医院眼科（冯燕兵，翁文庆）
Author(s):
FENG Yan-Bing; ZHU Jie-Yun ; WENG Wen-Qing
Zhejiang Chinese Medical University ( FENG Yan-Bing, ZHU Jie-Yun ) , Hangzhou 310053 , Zhejiang Province . China; Department of Ophthalmology ,Jiaxing Hospital of Traditional Chinese Medicine ( FENG Yan-Bing, WENG Wen-Qing ) , Jiaxing 314001 , Zhejiang Province , China
关键词:
Ozurdex; 缓释系统; 黄斑水肿
Keywords:
Ozurdex ;  sustained-release system ;  macular edema
分类号:
Ｒ７７４
DOI:
10.13389/j.cnki.rao.2016.0239
文献标志码:
A
摘要:
黄斑水肿是眼底病患者视力丧失的主要原因之一。多种因素导致血-视网膜屏障功能障碍，使血管通透性改变，血管内成分渗漏引起黄斑区水肿增厚。黄斑水肿的治疗方法多种多样，如黄斑激光光凝治疗、玻璃体内注射曲安奈德或抗血管内皮生长因子药物等都获得一定疗效。然而，它们仍各自存在局限性。近年来，生物可降解激素缓释剂为临床提供另外一种治疗选择。单独或联合应用取得了较好的临床疗效，其生物可降解及持续释放特点减少了术源性并发症，延长了药物作用时间。本文就Ｏｚｕｒｄｅｘ的结构特性，其在糖尿病视网膜病变、视网膜静脉阻塞、葡萄膜炎、玻璃体切割术后黄斑水肿患者的临床试验以及其长期疗效和安全性的相关研究进行综述。
Abstract:
Macular edema is one of the leading causes of vision loss among patients with fundus diseases. Many factors lead to blood retinal barrier dysfunction, which induced edema thickening of the macular region due to the change of blood vessel permeability and intravascular component leakages. Methods for macular edema are various , such as macular laser photocoagulation. intravitreal injection of triamanolone acetonide or anti-VEGF drugs effective. However , they still have some limitations. In recent years , application of biodegradable hormone sustained-release agent in clinic provides a new and effective treatment options. Separate or combined application should have achieved good clinical efficacy. The biodegradable and sustained release characteristics reduce operation complication , and prolong the time of drug action. In this article . according the characteristics of Ozurdexs structure ,its application in diabetic retinopathy , retinal vein occlusion . uveitis . macular edema of vitrectomized patients with clinical trials and long-term efficacy and safety are reviewed.

相似文献/References:

[1]赵勇 张卯年 任兵.激素缓释系统治疗糖尿病黄斑水肿新进展[J].眼科新进展,2012,32(10):000.
[2]赵玉新 吴明星.可生物降解载药性晶状体囊袋张力环抑制后发性白内障的研究进展[J].眼科新进展,2009,29(1):000.
[3]方丽英,黄宝宇,黄敏丽.Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效对比[J].眼科新进展,2021,41(3):231.[doi:10.13389/j.cnki.rao.2021.0048]
　FANG Liying,HUANG Baoyu,HUANG Minli.Comparison of the curative effect of Ozurdex and conbercept in the treatment of macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2021,41(9):231.[doi:10.13389/j.cnki.rao.2021.0048]
[4]丁浩轩,孙丽霞,吴沙仁高娃,等.Ozurdex治疗不同OCT分型的糖尿病性黄斑水肿患者的疗效和安全性[J].眼科新进展,2021,41(10):952.[doi:10.13389/j.cnki.rao.2021.0200]
　DING Haoxuan,SUN Lixia,WU Sharengaowa,et al.Efficacy and safety of Ozurdex in the treatment of patients with diabetic macular edema of different OCT types[J].Recent Advances in Ophthalmology,2021,41(9):952.[doi:10.13389/j.cnki.rao.2021.0200]
[5]白小芳,赵芃芃,秦梅,等.雷珠单抗联合Ozurdex治疗视网膜分支静脉阻塞继发黄斑水肿的疗效观察[J].眼科新进展,2022,42(5):394.[doi:10.13389/j.cnki.rao.2022.0080]
　BAI Xiaofang,ZHAO Pengpeng,QIN Mei,et al.Clinical effect of Ranibizumab combined with Ozurdex in the treatment of macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2022,42(9):394.[doi:10.13389/j.cnki.rao.2022.0080]

更新日期/Last Update: 2016-09-09